{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-062837","form_type":"8-K","ticker":"CLRB","cik":"0001279704","company_name":"Cellectar Biosciences, Inc.","filed_at":"2025-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.824645+00:00","generated_at":"2026-05-18T17:32:24.554859+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cellectar provides clinical updates, plans Phase 1 studies for CLR 125 and CLR 225 in H2 2025 subject to financing","bullets":["CLR 125 (Auger-emitting PRC) Phase 1b study in triple-negative breast cancer planned for H2 2025, subject to additional financing.","CLR 225 (alpha-emitting, actinium-225) Phase 1 imaging and dose-escalation safety study in solid tumors planned for H2 2025, subject to financing.","CLOVER-WaM study of iopofosine I 131 in Waldenström macroglobulinemia met primary endpoint with MRR of 58.2% (p<0.0001), ORR 83.6%, and 7.3% CR rate.","No treatment-related deaths in CLOVER-WaM study; most common Grade 3+ TRAEs were thrombocytopenia (81.5%) and neutropenia (66.2%), all patients recovered.","Proposed securities offering to fund operating expenses and initiate CLR 125 and CLR 225 clinical studies."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-062837","json":"https://secwatch.observer/filing/0001104659-25-062837.json","markdown":"https://secwatch.observer/filing/0001104659-25-062837.md","text":"https://secwatch.observer/filing/0001104659-25-062837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/0001104659-25-062837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465925062837/tm2519054d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T17:32:24.554859+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}